Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Verus Pharmaceuticals grosses $78mm with first venture round

Executive Summary

Pediatric specialty drug company Verus Pharmaceuticals has raised $78mm with its Series A venture round of preferred shares led by Domain Associates and Prospect Venture Partners. Other backers included the Paul Royalty Fund (managed by Paul Capital Partners), MPM Capital, Montreux Equity Partners, Athenian Venture Partners, Windamere, and private investors. Paul Royalty provided an additional $20mm in exchange for royalties on at least one undisclosed product.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies